Primus In News
Indian pharma ramps up US acquisitions amid regulatory and market shifts
15-03-2025
Nilaya Varma, CEO & Co-Founder, Primus Partners, and Vivek Tandon, Vice President, Primus Partners, share their view on the expansion of Indian pharmaceutical companies in the US through strategic acquisitions. They highlight Sun Pharma’s $355 million acquisition of Checkpoint Therapeutics as a key move to bolster its oncology and immunotherapy portfolio.
Explore Related Insights
- Prolonged instability in Bangladesh may disrupt reactive dyes industry for next one year
- NREGA outlay, cap on state borrowing hiked in fifth round
- Immunity Products, Tele-Medicine, Household Gadgets Driving Consumer Demand In Covid Times: ASSOCHAM-PRIMUS Report
- Infosys to Reliance: Gauging the economy through Q1 corporate results